Molecular Partners : Annual General Meeting Minutes
Minutes of the 19th Annual General Meeting of the Shareholders of MOLECULAR PARTNERS AG, held at 9:00 a.m. on 17 April 2024 at JED Events, Zürcherstrasse 39,...
Source: marketscreener.com
📰 Michael Vasconcelles News
Michael Vasconcelles News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Michael Vasconcelles. Real-time updates on events, politics, business and more.
FDA Prioritizes Review of Elahere in Ovarian Cancer
The Food and Drug Administration has set priority review for Elahrere as use of treatment in patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Michael Vasconcelles Drug Administration Immunogen Inc Biologics License Application Prescription Drug User Fee Ovarian Cancer
Source: curetoday.com
ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH
Pivekimab Triplet Demonstrates Encouraging CR, Composite CR, and MRD Negativity Rates; Broad Anti-Leukemia Activity Observed Across All Molecular Subsets Evaluated Pivekimab-Containing Triplet...
Source: marketscreener.com
FDA to Review Confirmatory Data for Elahere in Platinum-Resistant Ovarian Cancer
The FDA has accepted for Priority Review the sBLA supporting the conversion to full approval of Elahere for platinum-resistant ovarian cancer.
Michael Vasconcelles Drug Administration Priority Review Biologics License Application Executive Vice President Prescription Drug User Fee Act
Source: endocrinologyadvisor.com
FDA Grants Priority Review to Mirvetuximab Soravtansine in FRα+ Platinum-Resistant Ovarian Cancer
The FDA has granted priority review to the supplemental biologics license application seeking the conversion of the accelerated approval of mirvetuximab soravtansine-gynx in patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who previously received 1 to 3 lines of systemic treatment to full approval.
Michael Vasconcelles European Medicines Agency Acceptance China National Medical Products Administration P European Medicines Agency Immunogen Inc Prescription Drug User Fee Act
Source: onclive.com
FDA to Review Confirmatory Data for Elahere in Platinum-Resistant Ovarian Cancer
The FDA has accepted for Priority Review the sBLA supporting the conversion to full approval of Elahere for platinum-resistant ovarian cancer.
Michael Vasconcelles Drug Administration Priority Review Biologics License Application Executive Vice President Prescription Drug User Fee Act
Source: empr.com
FDA Grants Priority Review of ImmunoGen's Supplemental Biologics License Application for ELAHERE in Platinum-Resistant Ovarian Cancer
WALTHAM - ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that the US Food and Drug Administration has filed the...
United States Michael Vasconcelles Anabel Chan Courtney Okonek European Medicines Agency Company Quarterly Reports On Form
Source: marketscreener.com
ImmunoGen, Inc. (NASDAQ:IMGN) Q3 2023 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to ImmunoGens Third Quarter 2023 Financial and Operating Results Conference Call. Todays conference is being recorded.
Source: insidermonkey.com
ImmunoGen, Inc. (NASDAQ:IMGN) Q3 2023 Earnings Call Transcript
ImmunoGen, Inc. (NASDAQ:IMGN) Q3 2023 Earnings Call Transcript November 2, 2023 ImmunoGen, Inc. beats earnings expectations. Reported EPS is $0.1, expectations were $0.02. Operator: Good morning, ladies and gentlemen, and welcome to ImmunoGen’s Third Quarter 2023 Financial and Operating Results Conference Call. Today’s conference is being recorded. At this time, I’d like to turn the […]
Michael Vasconcelles Lauren White European Hematology Association Annual Meeting European Society Of Gynecologic Oncology Congress Annual European Society Gynecologic Oncology Congress
Source: yahoo.com
EMA Accepts Marketing Authorization Application for Mirvetuximab Soravtansine in FRα+, Platinum-Resistant Ovarian Cancer
The European Medicines Agency (EMA) has accepted a marketing authorization application seeking the approval of mirvetuximab soravtansine-gynx for the treatment of patients with folate receptor alpha–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Michael Vasconcelles European Medicines Agency European Medicines Agency Acceptance Image Credit Ovarian Cancer
Source: ajmc.com